‘The FDA Is Rarely That Clear’: What We Heard This Week


“The FDA isn’t that clear, so that is refreshing.” — Paul Knoepfler, PhD, of the College of California Davis, on the FDA getting harder on birth tissue injection companies, following a latest warning letter to at least one firm in query.
“Everyone seems to be in danger.” — Ziyad Al-Aly, MD, of Washington College in St. Louis, on avoiding an infection and reinfection within the first place to prevent long COVID.
“The overwhelming majority of eating places … deal with meals that’s not ready correctly, and will simply poison us, they usually do it day-after-day, thousands and thousands of instances a day.” — Jacob Sherkow, JD, of the Illinois Faculty of Drugs, in an analogy referring to the dangers that compounding pharmacies run in producing off-brand semaglutide (Wegovy).
“This strikes a chord for me. I’ve seen firsthand, each single day, how tough it may be for teenagers to entry care.” — Lisa Gwynn, MD, president of the Florida chapter of the American Academy of Pediatrics, on how advocating for equitable COVID vaccine entry for younger youngsters in her state cost her a spot on a state board.
“Till we have now a deal with on the entire endotypes, narrowing the scope of a definition can be an unmitigated catastrophe.” — David Putrino, PhD, of Mount Sinai Well being System in New York, advising the medical neighborhood to pump the breaks when deciding on a definition for long COVID.
“This stage of mortality is considerably greater than anticipated.” — David Boulware, MD, MPH, of the College of Minnesota in Minneapolis, on the excessive mortality fee in a small management group of hospitalized COVID-19 sufferers in a latest trial of the investigational treatment sabizabulin.